RevMed's pancreatic cancer drug Rasonque nears EU approval after FDA nod

European regulators recommended approval of Revolution Medicines' Rasonque for pancreatic cancer, following FDA approval. This expands treatment options for a difficult cancer, but market impact is limited to the company. The recommendation is a regulatory milestone, not a clinical breakthrough.